Search Results - "Ding, Philip Q."

Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada by Ding, Philip Q, Dolley, Aastha, Cheung, Winson Y

“…Gastric cancer mortality remains among the highest of all cancers. Trifluridine/tipiracil (FTD/TPI) represents Canada's first standard-of-care, third-line,…”
Get full text

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada by Yun, John Paul, Ding, Philip Q, Dolley, Aastha, Cheung, Winson Y

“…The management of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is limited and remains an unmet need. Decitabine/cedazuridine…”
Get full text

The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis by Breadner, Daniel, Loree, Jonathan M, Cheung, Winson Y, Gipson, Meghan, Lakkunarajah, Suganija, Mulder, Karen E, Spartlin, Jennifer L, Kong, Shiying, Ding, Philip Q, Gill, Sharlene, Welch, Stephen A

“…Abstract Background Colorectal cancer remains the second leading cause of cancer death in North America. Fluorouracil and oxaliplatin based adjuvant…”
Get full text

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma by Woo, Taylor E, Stukalin, Igor, Ding, Philip Q, Goutam, Siddhartha, Sander, Michael, Ewanchuk, Benjamin, Cheung, Winson Y, Heng, Daniel Y C, Cheng, Tina

“…: The majority of melanoma is diagnosed in individuals between 55 and 84 years old. Current data varied in reporting differences in survival outcomes amongst…”
Get full text

Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database by Grosjean, Heidi A I, Dolter, Samantha, Meyers, Daniel E, Ding, Philip Q, Stukalin, Igor, Goutam, Siddhartha, Kong, Shiying, Chu, Quincy, Heng, Daniel Y C, Bebb, D Gwyn, Morris, Don G, Cheung, Winson Y, Pabani, Aliyah

“…The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the…”
Get full text

Outcomes of hepatocellular carcinoma patients treated in the lenvatinib and immunotherapy era (2018–2021) compared to the sorafenib era (2008–2018) by Lim, Chloe A., Amaro, Carla P., Ding, Philip Q., Cheung, Winson Y., Tam, Vincent C.

“…Background Lenvatinib (LEN) and atezolizumab + bevacizumab (A + B) have drastically changed the treatment paradigm for advanced hepatocellular carcinoma (HCC)…”
Get full text

Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis by Rigo, Rodrigo, Doherty, Jordan, Koczka, Kim, Kong, Shiying, Ding, Philip Q., Cheng, Tina, Cheung, Winson Y., Monzon, Jose G.

“…Immune checkpoint and MAP kinase pathway inhibitors can significantly improve long-term survival for patients with melanoma. There is limited real-world data…”
Get full text

Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab by Goutam, Siddhartha, Stukalin, Igor, Ewanchuk, Benjamin, Sander, Michael, Ding, Philip Q, Meyers, Daniel E, Heng, Daniel, Cheung, Winson Y, Cheng, Tina

“…Immune checkpoint inhibitors (ICIs) for treatment of metastatic melanoma (MM) offer lasting overall survival (OS) benefit in a subset of patients. However,…”
Get full text

Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study by Rigo, Rodrigo, Ding, Philip Q, Batuyong, Eugene, Cheung, Winson Y, Walker, John, Monzon, Jose G, Cheng, Tina

“…Adjuvant therapies have been approved for resected melanoma based on improved recurrence-free survival. We present early findings from a real-world study on…”
Get full text

Real-World Use of Granulocyte-Colony Stimulating Factor in Patients with Breast Cancer from Alberta, Canada by Ding, Philip Q, Newcomer, Brandt J, Cheung, Winson Y

“…There are limited published data in the Canadian healthcare system on the use of granulocyte colony-stimulating factor (G-CSF) among patients with breast…”
Get full text

Cost-Effectiveness of Surveillance after Metastasectomy of Stage IV Colorectal Cancer by Ding, Philip Q, Au, Flora, Cheung, Winson Y, Heitman, Steven J, Lee-Ying, Richard

“…Surveillance of stage IV colorectal cancer (CRC) after curative-intent metastasectomy can be effective for detecting asymptomatic recurrence. Guidelines for…”
Get full text

Obesity and Its Impact on Outcomes in Patients With Stage III Colon Cancer Receiving Adjuvant Chemotherapy by Ding, Philip Q., Batra, Atul, Xu, Yuan, McKinnon, Geoffrey P., Cheung, Winson Y.

“…Even though obesity is a well-established risk factor for developing colon cancer, its prognostic value is not very well understood. The present study…”
Get full text

Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications by Lee, Cha Len, Freeman, Mark, Burak, Kelly W, Moffat, Gordon T, O'Donnell, Conor D J, Ding, Philip Q, Lyubetska, Hanna, Meyers, Brandon M, Gordon, Vallerie, Kosyachkova, Ekaterina, Bucur, Roxana, Cheung, Winson Y, Knox, Jennifer J, Tam, Vincent C

“…The IMbrave150 trial established atezolizumab with bevacizumab (A+B) as standard care for hepatocellular carcinoma (HCC), recommending an…”
Get full text

Outcomes of patients with hepatocellular carcinoma (HCC) treated in the lenvatinib (LEN) and immunotherapy era (2018-2021) compared to the sorafenib (SOR) era (2008-2018) by Lim, Chloe, Amaro, Carla Pires, Ding, Philip Q., Cheung, Winson Y., Tam, Vincent C.

“…553 Background: SOR was the standard first-line treatment for HCC for about a decade until the approval of LEN. Subsequently, atezolizumab + bevacizumab (A+B)…”
Get full text

Trends and disparities in the treatment of older adults with colon cancer by Ding, Philip Q., Brenner, Darren R, O'Sullivan, Dylan E., Cheung, Winson Y.

“…e18776 Background: Adults aged ≥70 years represent approximately half of all patients diagnosed with colon cancer (CC), but undertreatment in this population…”
Get full text

Real-world associations among patient-physician sex concordance, treatment practices, and cancer outcomes by Ding, Philip Q., O'Sullivan, Dylan E., Shamsi, Rubab, Wada, Aisha, Farrer, Christie, Cuthbert, Colleen Ann, Brenner, Darren R, Cheung, Winson Y.

“…e18511 Background: Prior research has linked patient-physician sex discordance with inferior surgical and cardiac outcomes. The impact of such sex inequities…”
Get full text

Atezolizumab + bevacizumab versus lenvatinib as first-line systemic therapy for treatment of hepatocellular carcinoma in a real-world population: Outcomes from the HCC CHORD database by Freeman, Mark, Krishnan, Tharani, LEE, Cha Len, Dibajnia, Pooya, Ramjeesingh, Ravi, Solar Vasconcelos, Joao Paulo, Lyubetska, Hanna, Ding, Philip Q., Lim, Howard J, Knox, Jennifer J., Meyers, Brandon M., Gordon, Vallerie Lynn, Cheung, Winson Y., Tam, Vincent C.

“…4111 Background: Lenvatinib (LEN) and the combination of atezolizumab with bevacizumab (AB) are widely considered first-line systemic therapies for the…”
Get full text

Real-world multicentre analysis of patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (A+B): Efficacy, esophagogastroduodenoscopy (EGD) uptake and bleeding complications by LEE, Cha Len, Freeman, Mark, O'Donnell, Conor, Moffat, Gordon Taylor, Kosyachkova, Ekaterina, Lyubetska, Hanna, Meyers, Brandon M., Gordon, Vallerie Lynn, Ding, Philip Q., Kay, Aileigh, Bucur, Roxana, Cheung, Winson Y., Knox, Jennifer J., Tam, Vincent C.

“…4105 Background: The IMbrave150 trial established A+B as a standard of care for HCC and an EGD within 6 months (mos) of starting treatment to detect…”
Get full text